Drug Discovery Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

The Drug Discovery Market is segmented by Drug Type (Small Molecule Drugs and Biologic Drugs), Technology (High Throughput Screening, Pharmacogenomics, Combinatorial Chemistry, Nanotechnology, and Other Technologies), End User (Pharmaceutical Companies, Contract Research Organizations (CROs), and Other End Users), and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The report offers the value (in USD million) for the above segments.

Market Snapshot

Study Period:

2018-2026

Base Year:

2020

Fastest Growing Market:

Asia Pacific

Largest Market:

North America

CAGR:

8.3 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The drug discovery market is expected to register a CAGR of nearly 8.3% during the forecast period, with a revenue of approximately USD 53,855 million in 2020, and it is expected to reach 85,785 million by 2026.

Amid the COVID-19 pandemic, the health system of countries is rapidly investing in research and development to combat the virus. Potential compounds were screened from the CHEMBL database, ZINC database, FDA approved drugs, and molecules under clinical trials. Research groups across the world are identifying drugs for the treatment of COVID-19, by screening both novel and existing drugs for their ability to alleviate symptoms and stem viral replication. Thus, in view of the ongoing pandemic, the drug discovery market is expected to be positively impacted by the urge to find a cure for COVID-19.

The propelling factors for the growth of the drug discovery market include the rising burden of a wide range of diseases (such as cardiovascular and CNS-related disorders), rising healthcare expenditure, and upcoming patent expiration of blockbuster drugs.

Cardiovascular diseases, infectious diseases, diabetes, and kidney-related complications have high burden, globally. For instance, according to the estimates of the Heart Disease and Stroke Statistics 2019, approximately 116.4 million, or 46% of adults in the United States were estimated to have hypertension.

Also, according to the American Cancer Society, in 2020, about 1.8 million new cancer cases are expected to be diagnosed, and approximately 606,520 cancer deaths may occur in the United States. Thus, the increasing burden of a diverse range of diseases among all age groups and its burden, globally, drive the demand for drug discovery and its market.

There has been an upsurge in the usage of advanced technologies, such as high throughput, bioinformatics, and combinatorial chemistry for better drug candidate identification. Drug discovery has evolved significantly with emerging technologies, helping the process to become more refined, accurate, and less time consuming. The adoption of artificial intelligence systems in disease diagnostics and treatment design started growing, and this is expected to witness robust growth in the coming years. For instance, on March 31, 2020, Existencia, an AI-based drug discovery company, entered a collaborative agreement with Diamond Light Source and Scripps Research for identifying COVID-19 antiviral therapies. It is anticipated to contribute to the growth of the market over the forecast period.

The gradual rise in the healthcare expenditure regionally helps the new pharmaceutical technology advancement. Although with high expenditure, there is a need for redirecting the resources.

Scope of the Report

As per the scope of the report, drug discovery is a process, which aims at identifying a compound therapeutically useful in treating and curing diseases. Typically, a drug discovery effort addresses a biological target that has been shown to play a role in the development of the disease or starts from a molecule with interesting biological activities. In the recent past, drug discovery has evolved significantly with emerging technologies, helping the process to become more refined, accurate, and less time-consuming. The drug discovery market is segmented by drug type (small molecule drugs and biologic drugs), technology (high throughput screening, pharmacogenomics, combinatorial chemistry, nanotechnology, and other technologies), end user (pharmaceutical companies, contract research organizations (CROs), and other end users), and geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The market report also covers the estimated market sizes and trends of 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.

Drug Type
Small Molecule Drugs
Biologic Drugs
Technology
High Throughput Screening
Pharmacogenomics
Combinatorial Chemistry
Nanotechnology
Other Technologies
End User
Pharmaceutical Companies
Contract Research Organizations (CROs)
Other End Users
Geography
North America
United States (By Drug Type, By Technology, and By End User)
Canada (By Drug Type, By Technology, and By End User)
Mexico (By Drug Type, By Technology, and By End User)
Europe
United Kingdom (By Drug Type, By Technology, and By End User)
Germany (By Drug Type, By Technology, and By End User)
France (By Drug Type, By Technology, and By End User)
Italy (By Drug Type, By Technology, and By End User)
Spain (By Drug Type, By Technology, and By End User)
Rest of Europe (By Drug Type, By Technology, and By End User)
Asia-Pacific
China (By Drug Type, By Technology, and By End User)
Japan (By Drug Type, By Technology, and By End User)
India (By Drug Type, By Technology, and By End User)
Australia (By Drug Type, By Technology, and By End User)
South Korea (By Drug Type, By Technology, and By End User)
Rest of Asia-Pacific (By Drug Type, By Technology, and By End User)
Middle-East and Africa
GCC (By Drug Type, By Technology, and By End User)
South Africa (By Drug Type, By Technology, and By End User)
Rest of Middle-East and Africa (By Drug Type, By Technology, and By End User)
South America
Brazil (By Drug Type, By Technology, and By End User)
Argentina (By Drug Type, By Technology, and By End User)
Rest of South America (By Drug Type, By Technology, and By End User)

Report scope can be customized per your requirements. Click here.

Key Market Trends

Biologics Drug is the Segment that is Expected to Grow Fastest Under Drug Type

Biologics and drugs offer several benefits, such as highly effective and potent action, fewer side effects, and the potential to actually cure the diseases rather than merely treat the symptoms, which significantly increased the demand for these products.​

The efficacy and safety of biopharmaceuticals have led to their rapid adoption by people, driving the global drug discovery market. As per the report of Pharmaceutical Research and Manufacturers of America 2019, biopharmaceutical products have shown positive results for some of the chronic and rare diseases, which led to its sharp rise in the demand.

As per the study of Journal of Family Medicine and Primary care 2020, about 12 out of 46 drugs were anticancer agents in 2017, and in 2018, about 23 out of 55 were anticancer drugs.

As per the same study, the number of New Drug Applications (NDAs)/Biologic License Applications (BLA’s) registered per year has seen a significant increase over the past decade. In 2017, around 46 agents were approved, while in 2018, around 59 novel agents were approved. Therefore, it is expected to further drive the market studied over the forecast period.

In the pandemic, the rising adoption of biologics due to the certain advantages associated with them, especially target specificity, is boding well for the market studied. A significant number of major biotech firms are in the middle of a race to investigate the Sars-Cov-2 genome and prepare therapeutics for the same. For instance, in November 2020, South Korean pharma company Samsung Biologics entered a long-term agreement with Eli Lilly and Company to manufacture its investigational COVID-19 virus-neutralizing antibody, bamlanivimab.​Therefore, it is expected to further drive the market studied over the forecast period.

To understand key trends, Download Sample Report

North America is Expected to Hold the Largest Market Share Over the Forecast Period

North America leads the world in terms of R&D spending on pharmaceuticals. It is also the largest market for bulk drugs and finished dosage formulations. The market operates as a free economy, which is designed to implement transparent trade practices and restrict anti-competitive practices.​​

A major push for generic drugs and biosimilars is expected to boost the demand for specialty and complex ingredients, over the forecast period. ​For instance, in 2019, Biocon and Mylan jointly launched a cancer drug called Ogivri, a biosimilar to Herceptin, in the United States. Herceptin is a biologic therapeutic used for the treatment of all types of breast cancers and metastatic stomach cancers (gastric or gastroesophageal junction adenocarcinoma). ​

Also, in November 2019, Genesis Therapeutics announced that it raised USD 4.1 million in seed funding led by Andreessen Horowitz. This company is harnessing breakthrough AI-technology to optimize drug discovery and development.

Furthermore, the country has great opportunities for biosimilars, as biologics carry higher price. By 2020, the US market is estimated to become one of the major competitors of biosimilars. The key products in the US market are Remicade, Enbrel, Rituximab, Adalimumab, Infliximab, Etanercept, Darbepoetin Alpha, etc. Hence, owing to the aforementioned factors, the market is estimated to witness a high growth over the forecast period.

The COVID-19 pandemic highlighted the need for North American companies and research organizations to collaborate with the government to develop new drugs, in order to meet future health crises. Several universities and key players are focusing on developing vaccines for coronavirus. For instance, Eli Lilly partnered with AbCellera for the development of vaccines. Thus, this is expected to further boost the market studied over the forecast period.

To understand geography trends, Download Sample Report.

Competitive Landscape

The market studied has various pharmaceutical companies that are investing billions of dollars in artificial intelligence (AI), in order to make the drug discovery process significantly faster and cost-efficient. The pharmaceutical and biotech companies are increasing their collaborations with contract development and manufacturing organizations.

Recent Developments

  • In November 2020, Genesis Therapeutics entered AI-driven, multi-target drug discovery partnership with Genentech. The collaboration leverages Genesis’ graph machine learning and drug discovery expertise to identify innovative drug candidates for therapeutic targets in multiple disease areas.
  • In January 2020, Bayer entered a collaboration agreement with artificial intelligence drug discovery company Exscientia, to identify and optimize novel lead structures for potential drug candidates in treating cardiovascular and oncological diseases.

You can also purchase parts of this report. Do you want to check out a section wise price list?

Table Of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Rising Burden of Various Chronic Diseases

      2. 4.2.2 Increasing Research and Development Expenditure and Investment for Development of Novel Drug Molecules

    3. 4.3 Market Restraints

      1. 4.3.1 Huge Capital Investment with Low Profit Margins

      2. 4.3.2 Stringent Government Regulations

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 Drug Type

      1. 5.1.1 Small Molecule Drugs

      2. 5.1.2 Biologic Drugs

    2. 5.2 Technology

      1. 5.2.1 High Throughput Screening

      2. 5.2.2 Pharmacogenomics

      3. 5.2.3 Combinatorial Chemistry

      4. 5.2.4 Nanotechnology

      5. 5.2.5 Other Technologies

    3. 5.3 End User

      1. 5.3.1 Pharmaceutical Companies

      2. 5.3.2 Contract Research Organizations (CROs)

      3. 5.3.3 Other End Users

    4. 5.4 Geography

      1. 5.4.1 North America

        1. 5.4.1.1 United States (By Drug Type, By Technology, and By End User)

        2. 5.4.1.2 Canada (By Drug Type, By Technology, and By End User)

        3. 5.4.1.3 Mexico (By Drug Type, By Technology, and By End User)

      2. 5.4.2 Europe

        1. 5.4.2.1 United Kingdom (By Drug Type, By Technology, and By End User)

        2. 5.4.2.2 Germany (By Drug Type, By Technology, and By End User)

        3. 5.4.2.3 France (By Drug Type, By Technology, and By End User)

        4. 5.4.2.4 Italy (By Drug Type, By Technology, and By End User)

        5. 5.4.2.5 Spain (By Drug Type, By Technology, and By End User)

        6. 5.4.2.6 Rest of Europe (By Drug Type, By Technology, and By End User)

      3. 5.4.3 Asia-Pacific

        1. 5.4.3.1 China (By Drug Type, By Technology, and By End User)

        2. 5.4.3.2 Japan (By Drug Type, By Technology, and By End User)

        3. 5.4.3.3 India (By Drug Type, By Technology, and By End User)

        4. 5.4.3.4 Australia (By Drug Type, By Technology, and By End User)

        5. 5.4.3.5 South Korea (By Drug Type, By Technology, and By End User)

        6. 5.4.3.6 Rest of Asia-Pacific (By Drug Type, By Technology, and By End User)

      4. 5.4.4 Middle-East and Africa

        1. 5.4.4.1 GCC (By Drug Type, By Technology, and By End User)

        2. 5.4.4.2 South Africa (By Drug Type, By Technology, and By End User)

        3. 5.4.4.3 Rest of Middle-East and Africa (By Drug Type, By Technology, and By End User)

      5. 5.4.5 South America

        1. 5.4.5.1 Brazil (By Drug Type, By Technology, and By End User)

        2. 5.4.5.2 Argentina (By Drug Type, By Technology, and By End User)

        3. 5.4.5.3 Rest of South America (By Drug Type, By Technology, and By End User)

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Genome Biologics

      2. 6.1.2 Abbott Laboratories Inc.

      3. 6.1.3 Agilent Technologies Inc.

      4. 6.1.4 AstraZeneca PLC

      5. 6.1.5 AVIVA Biosciences

      6. 6.1.6 Bayer AG

      7. 6.1.7 Biotica Pharma

      8. 6.1.8 Bristol-Myers Squibb Company

      9. 6.1.9 Collaborative Drug Discovery Inc.

      10. 6.1.10 DeepBiome Therapeutics

      11. 6.1.11 Eli Lilly and Company

      12. 6.1.12 F. Hoffmann-La Roche Ltd

      13. 6.1.13 Gilead Sciences Inc.

      14. 6.1.14 GlaxoSmithKline PLC

      15. 6.1.15 Merck & Co. Inc.

      16. 6.1.16 Novartis

      17. 6.1.17 Pfizer Inc.

      18. 6.1.18 Shimadzu Corp.

      19. 6.1.19 Takeda Pharmaceuticals

      20. 6.1.20 Teva Pharmaceuticals

  7. *List Not Exhaustive
  8. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape Covers - Business Overview, Financials, Products and Strategies, and Recent Developments

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Related Reports